Participant Flow Module
The Participant Flow Module provides information about the flow of participants through each stage of the clinical trial. This includes pre-assignment details, recruitment information, and the types of units analyzed, helping researchers understand how participants move through the study.
Participant Flow Module path is as follows:
Study -> Results Section -> Participant Flow Module
Participant Flow Module
Ignite Creation Date:
2025-12-24 @ 11:08 PM
Ignite Modification Date:
2025-12-25 @ 8:41 PM
NCT ID:
NCT04642469
Pre Assignment Details:
30 participants were randomized in a 1:1 ratio to receive durvalumab monotherapy or placebo in the study.
Recruitment Details:
This Phase III multicenter, double-blind, placebo-controlled study was conducted in participants with Stage II to III non-small cell lung cancer (NSCLC) at 21 sites in 13 countries (Australia, Brazil, Czech Republic, France, Greece, Hungary, Israel, Italy, Japan, Spain, Taiwan, Turkey, and United States). First participant was enrolled on 30-Nov-2020 and final data cut-off (DCO) date was 31 May 2023.
Study:
NCT04642469
Study Brief:
Results Section:
NCT04642469